Message Font: Serif | Sans-Serif
No. of Recommendations: 2
7:14AM Boston Scientific Anemic For Now -- BWeek (BSX) 33.60: BusinessWeek's Inside Wall St section highlights Boston Scientific when has fallen since its summer recall of 100,000 coronary stents and since its lowered Q4 guidance. But John Maloney of M&R Capital Mgmt, which owns stock, says that BSX -- a maker of surgical devices for cardiology, oncology, and urology -- is too undervalued to ignore. With its leadership in stents (70% of the market vs. 30% for Johnson & Johnson (JNJ)) and its "rich pipeline" of other products, BSX shouldn't be trading so low, he argues. "It is the cheapest in the medical-device group," he says, selling at only 15x 2005 EPS, and 13.6x 2006. His 12-to-18-month target: $50 -- or 20x his 2006 estimate. BSX may lose market share in stents, he says, as competition heats up, but it will remain No. 1. Non-stent products, such as tools for cardiac surgery, will offset any loss.
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.